The US Food and Drug Administration (FDA) approved sarilumab (Kevzara) today for the treatment of polymyalgia rheumatica (PMR) in adults who have had an inadequate response to corticosteroids or could ...

Please provide your email address to receive an email when new articles are posted on . Patients were more likely to achieve sustained remission with sarilumab vs. placebo. The most common adverse ...

Are you struggling with persistent pain and stiffness in your shoulders, neck or hips beyond the usual aches and pains of aging? Polymyalgia rheumatica, a common inflammatory rheumatic disease ...

Topline data were announced from a phase 3 trial evaluating secukinumab in patients with polymyalgia rheumatica.

The approval was based on data from a phase 3 study which included adults with steroid-resistant active PMR who flared on at least 7.5mg per day of prednisone or equivalent during taper. The Food and ...

PORTLAND, Ore.--(BUSINESS WIRE)--Sparrow Pharmaceuticals today announced that it presented new data from its ongoing Phase 2 clinical trial of its HSD-1 inhibitor, clofutriben (referred to SPI-62 in ...

Learn about polymyalgia rheumatica, temporal arteritis, their symptoms, causes, and treatment options to manage pain, ...

Background: the mainstay of treatment of polymyalgia rheumatica (PMR) is oral glucocorticoids, but randomized controlled trials of treatment are lacking. As a result, there is no evidence from ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Diagnosing giant cell arteritis and polymyalgia rheumatica can “fascinate” and cause “trepidation” ...

Novartis said that its immunology drug Cosentyx met the primary target and all secondary ones in a late-stage trial for the treatment of patients with inflammatory disease polymyalgia rheumatica.

PORTLAND, Ore.--(BUSINESS WIRE)--Sparrow Pharmaceuticals, a clinical-stage biopharmaceutical company that develops novel, targeted therapies to address unmet needs in both endocrinology and ...